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Aim: To investigate the regulatory potential of intergenic/intronic hypomethylated regions (iHMRs) within
imprinted domains. Materials & methods: Based on the preliminary results of the histone modification
and conservation profiles, we conducted reporter assays on the Peg3 and H19 domain iHMRs. The in
vitro results were confirmed by the in vivo deletion of Peg3-iHMR designed to test its function in the
Peg3 imprinted domain. Results & conclusion: Initial bioinformatic analyses suggested that some iHMRs
may be noncanonical enhancers for imprinted genes. Consistent with this, Peg3- and H19-iHMRs showed
context-dependent promoter and enhancer activity. Further, deletion of Peg3-iHMR resulted in allele- and
sex-specific misregulation of several imprinted genes within the domain. Taken together, these results
suggest that some iHMRs may function as domain-wide regulators for the associated imprinted domains.
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Genomic imprinting is a unique epigenetic regulatory mechanism in placental mammals by which a subset of
genes are expressed in a parental allele-specific fashion. These genes generally share roles in embryonic and neonatal
growth regulation as well as brain development and behavior [1]. A fraction of imprinted genes also shows signs of
tumor suppressor activity and susceptibility to epigenetic changes in many cancer states [2,3]. Only a few hundred
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genes are subjected to genomic imprinting in the mammalian genome, and they are typically found clustered in
relatively conserved domains of about 500 kilobases (kb) to two megabases (Mb) in length [1,4]. Imprinted genes
within a domain are known to be co-regulated, based on the juxtaposition of reciprocally imprinted genes, as well
as their frequently shared spatial and temporal expression patterns [1,5,6]. This co-regulation is mediated through
regulatory elements called imprinting control regions (ICR). ICRs obtain DNA methylation during gametogenesis
and maintain the allele-specific DNA methylation in somatic cells throughout the lifetime of eutherians. ICRs
are also responsible for the imprinting and transcriptional regulation of entire imprinted domains [1,7]. However,
besides ICRs, not much is currently known regarding the cis-regulatory elements that impact imprinted gene
expression, although other enhancer-like regions have been predicted to direct the spatial and temporal expression
patterns of imprinted genes [5,7–10].
In this postgenomic era, many potential regulatory elements have been revealed through high-throughput
sequencing. One such class of elements is the intergenic/intronic hypomethylated region (iHMR), which are often
smaller, more tissue-specific and better indicative of gene activity than hypomethylated promoter regions. The
iHMRs have been characterized to resemble insulator, promoter, enhancer or bivalent elements [11]. In general,
insulator-like elements are transcriptionally silent and bound by CTCF [11], with potential roles in chromatin
domain organization [12]. Promoter- and enhancer-like iHMRs, on the other hand, are transcriptionally active
elements bound by various transcription factors and RNA polymerase II. The enhancer-like iHMRs, however,
are differentiated by their tissue-specific hypomethylation, as opposed to the constitutive hypomethylation pattern
observed at many promoter- and insulator-like elements [11]. A fair share of each of the classes of iHMRs is found
within imprinted domains, where they may act as enhancers, alternative promoters as well as chromatin architecture
regulators. The functions of all of the aforementioned categories of cis-regulatory elements have been previously
linked with the regulation of imprinting mechanism and/or imprinted gene expression patterns [13–17]. Moreover,
many of these elements also exhibit epigenetic aberrations in cancers where imprinted genes tend to be affected [2,3].
Therefore, identifying the role of iHMRs in imprinted domains could lead to a further understanding of how
imprinted genes are regulated in normal as well as clinically relevant states such as in cancer.
A few iHMRs have been previously characterized as evolutionarily conserved elements in the Peg3, H19 and Dlk1
domains. All three iHMRs are constitutively hypomethylated, and two of them bind CTCF. Yet, these iHMRs appear
more enhancer-like than insulator-like in terms of their epigenetic and functional states. The list of these elements
includes ECR18 (evolutionary conserved region 18) within the Peg3 domain [8,9], H19-CCD (central conserved
domain) within the H19/Igf2 domain [18] and Dlk1-CE4 (conserved element 4) in the Gtl2/Dlk1 domain [10].
Given the unusual co-regulation patterns of imprinted genes, we hypothesized that other such noncanonical
elements may also exist within imprinted domains that are involved in properly orchestrating gene expression
from opposite parental alleles. Thus, here we have surveyed five additional iHMRs within imprinted domains
that share hypomethylation patterns across multiple tissues, similar to the three previously described noncanonical
enhancer-like iHMRs. Analysis of the eight total elements suggest that many of these iHMRs may be transcriptional
regulators within imprinted domains, despite their nontraditional presentation. Moreover, CRISPR/Cas9-based
deletion of the intronic HMR, ECR18, affected multiple genes in the Peg3 domain, suggesting that some iHMRs
may even be regulators impacting the transcription of the entire imprinted domains.
Materials & methods
Bioinformatic analyses of iHMRs in imprinted domains
DNA methylation and histone modifications were visualized for eight intergenic/intronic hypomethylated regions
selected for this study using the publicly available datasets on UCSC Genome Browser (Supplementary Figure
1) [19,20]. Based on placental mammal conservation data (PhyloP track) from UCSC Genome Browser, the most
conserved 100–500 bp segment of the iHMR was selected for further analyses (Supplementary Material 1) [21].
Data from the MultiZ alignment tool in UCSC Genome Browser [22] were harnessed to retrieve orthologous
sequence for each iHMR for all available placental mammals. Additionally, the BLAT program was used to identify
orthologous iHMR sequences that had not been detected through the MultiZ alignment. Each of the sequences
were then aligned against the reference mouse sequence using blastn, and the percentage identity (ID) recorded
for all alignments ≥100 bp in length. Next, the alignments were manually surveyed for conserved DNA motifs,
based on chromatin immunoprecipitation (ChIP)-seq datasets from various mouse and human tissues, available
on UCSC Genome Browser [23–26]. Additionally, for five highly conserved iHMR, orthologous sequences from five
species – mouse, human, cat, horse and cow – were analyzed using DCODE to identify conserved transcription
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Figure 1. Intergenic/intronic hypomethylated regions in imprinted domains. (A) The various intronic hypomethylated regions of the
Gnas domain are depicted by dark blue bars [19,20]. The iHMR selected for this study is marked by a light blue bar and labeled as
‘Gnas-HMR’. Light blue bars also mark the other iHMRs selected for this study: (B) Peg3-ECR18 (Peg3 domain); (C) Ndn-HMR (Ndn
domain); (D) H19-HMR (H19 domain). (E) The four iHMRs selected from the Dlk1 domain are also marked and labeled as shown for the
Gnas domain in (A).
HMR: Hypomethylated regions; ICR: Imprinting control region; iHMR: Intergenic/intronic HMR.
factor-binding motifs [27]. The phylogenetic tree in Figure 4 was downloaded in Newick format from UCSC
Genome Browser and visualized using the PlyloPng program.
Combined Bisulfite Restriction Assay
Genomic DNA was isolated using phenol–chloroform (Invitrogen, Waltham, MA, USA) extraction, followed by
ethanol precipitation, from 14.5-days post coitum (dpc) whole embryo, 17.5-dpc embryo head and the following
adult tissues: brain, tail, kidney, spleen, lung and liver. Approximately 1 μg of genomic DNA was subjected to the
sodium bisulfite treatment using the EZ DNA Methylation™ kit (Zymo Research, Irvine, CA, USA). Next, 1 μl
(∼20 ng) of the bisulfite-converted DNA was amplified using several primer sets (Supplementary Material 2). The
PCR products were then digested with appropriate restriction enzymes to monitor the methylation level at the CpG
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Figure 1. Intergenic/intronic hypomethylated regions in imprinted domains (cont.). (A) The various intronic hypomethylated regions of
the Gnas domain are depicted by dark blue bars [19,20]. The iHMR selected for this study is marked by a light blue bar and labeled as
‘Gnas-HMR’. Light blue bars also mark the other iHMRs selected for this study: (B) Peg3-ECR18 (Peg3 domain); (C) Ndn-HMR (Ndn
domain); (D) H19-HMR (H19 domain). (E) The four iHMRs selected from the Dlk1 domain are also marked and labeled as shown for the
Gnas domain in (A).
HMR: Hypomethylated regions; ICR: Imprinting control region; iHMR: Intergenic/intronic HMR.
sites within their recognition sequences. In order to compare differences in DNA methylation between normal
and tumor tissues, each sample was tested at least three-times (starting with the bisulfite-conversion process). The
ImageJ program was subsequently used to quantify the relative band densities derived from the methylated and
unmethylated DNA fractions in each sample.
Chromatin immunoprecipitation
Chromatin prepared from mouse embryonic fibroblast (MEF) cells [28] was sonicated and divided into three
fractions. The first fraction was saved as input control. The second fraction was precleared with protein A/G
PLUS-agarose beads (Santa Cruz Biotechnology, Dallas, TX, USA), and treated with 5 μg of either anti-Pol II
(N-20: sc-899X, Santa Cruz Biotechnology) or anti-CTCF antibody (catalog number 07–729, Millipore Cor-
poration, Darmstadt, Germany). The third fraction was precleared, but without any antibody, thus serving as
the no-antibody (negative) control. The antibody/protein/DNA complex was precipitated using protein A/G
PLUS-agarose beads. Subsequently, all three fractions were decrosslinked, and the DNA were recovered by phenol–
chloroform (Invitrogen) extraction followed by ethanol precipitation.
One microliter DNA from all three fractions was then amplified using primers (Supplementary Material 2)
that were designed to flank the predicted transcription factor-binding motif and quantified by ChIP-qPCR
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Figure 2. Epigenetic profiling of intergenic/intronic hypomethylated region in imprinted domains. (A) Hypomethylation status of the
iHMRs in the respective tissue is shown in blue. Although some iHMRs are constitutively hypomethylated, others are hypomethylated at
various levels of tissue specificity. (B) Histone modification at iHMRs. Most of the iHMRs are marked by active histone marks (dark blue –
H3K4me1; gold – H3K27ac; green – H3K4me1 and H3K27ac; magenta – H3K4me3 and H3K27ac) in a tissue-specific manner.



































































































































Figure 3. DNA methylation of imprinted domain intergenic/intronic hypomethylated region in mice and humans.
Methylation level of the iHMRs were analyzed with COBRA in: (A) five adult mouse tissues; (B) two embryonic stages;
(C) within murine thymic lymphoma [3]; (D) at the orthologous region of the iHMRs in humans. Boxes underneath
COBRA images indicate hypermethylation (red), hypomethylation (green) and no significant change (gray) in tumor
tissues relative to the normal control. The band representing the methylated fraction of the DNA is marked with a red
‘M’ and the unmethylated fraction with a blue ‘U’.
Br-C: Breast cancer (unmatched); Br-mat-N: Matched breast normal; Br-mat-T: Matched breast
tumor; COBRA: Combined Bisulfite Restriction Assay; E: Early stage; iHMR: Intergenic/intronic hypomethylated
region; L: Late stage; Lu-C: Lung cancer (unmatched); Lu-mat-N: Matched lung normal; Lu-mat-T: Matched lung
tumor; M: Middle stage.
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Figure 4. Conservation profile of intergenic/intronic hypomethylated regions among placental mammals. The grayscale profile (darker
the gray, higher the percent identity as compared with the reference [mouse]) shows that the iHMRs are relatively well conserved overall,
and harbor some conserved DNA-binding motifs, such as CTCF (‘C’) and E-box (‘E’/‘e’). Upper case ‘E’ indicates that the actual sequence
within the motifs are conserved in the respective species as compared with mouse. Lower case ‘e’ indicates the presence of a different
version of the DNA-binding motif.
iHMR: Intergenic/intronic hypomethylated region.
(QuantStudio 6, Invitrogen). The Ct values for each amplicon derived from the no-antibody control (Neg)
and immunoprecipitated DNA (Ab) were normalized against those from the input.
Reporter assays
A promoterless luciferase reporter construct [9] was modified by cloning Peg3-ECR18 (chr7:6866573–6866967)
or a 1649 bp region of the H19-HMR (chr7:149796116–49797764) in both forward and reverse orientations
upstream of the luc2 gene. Enhancer activity for Peg3-ECR18 [9] and H19-HMR was tested by cloning the regions
(as described for the promoter assay) upstream of the main promoter from each of their imprinted domains (Peg3
and H19, respectively) in the luc2 reporter construct. HEK 293T, HeLa, Neuro2A and 3T3 cells were grown in a
T-75 flask with Dulbecco’s modified Eagle medium Plus GlutaMAX medium (DMEM; Fisher Scientific, Pittsburg,
PA, USA) containing 10% fetal bovine serum (FBS; Fisher Scientific) and 1% antibiotic-antimycotic (A-A;
Corning, Tewksbury, MA, USA). Cells were co-transfected with 2 μg of a luciferase reporter construct in a 6-well
plate along with 2 μg of a β-geo reporter construct to monitor transfection efficiency. Transfections for HEK
293T, HeLa and Neuro2A cells were performed with 10 μl Lipofectamine 2000 (Invitrogen). Transfection medium
(DMEM without FBS and A-A) was replaced with fresh culture medium (DMEM with 10% FBS, 1% A-A) 5.5 h
post-transfection. The 3T3 cells were transfected using 6 μl GenJet in vitro DNA Transfection Reagent for 3T3
Cells (SignaGen Laboratories, Rockville, MD, USA), according to the manufacturer’s protocol. Three independent
transfections were performed for each set of reporter constructs in all four cell lines. The cells were subsequently
harvested 48 h post-transfection in 250 μl of the reporter lysis buffer (0.1 M Tris-Cl, pH 7.8, 0.1% NP-40). Due
to very low number of 3T3 cells, the three replicate transfections were combined when harvesting the cells (in total,
250 μl reporter lysis buffer) for the luciferase and β-galactosidase assays. The luciferase assays were conducted using
a commercial reagent according to manufacturer’s protocol (Promega, Fitchburg, WI, USA), and the readings were
normalized against β-galactosidase activity. The graphs in Figure 6 show one representative transfection experiment
450 Epigenomics (2018) 10(4) future science group












































Figure 5. CTCF and RNA polymerase II binding at imprinted domain intergenic/intronic hypomethylated regions.
Top: enrichment (Ab) for CTCF (dark green) and Pol II (dark blue) is shown as a percentage of the input DNA,
compared with the no-antibody control (Neg; CTCF, light green; Pol II, light blue). Error bars show standard deviation
between technical replicates. Bottom: significant enrichment of antibody (Ab) over control (Neg) is shown as a filled
box for CTCF (green) and Pol II (blue). All normalized enrichment <1% of input DNA (gray bar) was ignored from the
analysis.
*p ≤ 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; *****p < 0.00001 (Student’s t-test).
N.D.: Not detected.
for HEK 293T, HeLa and Neuro2A cells and the combined readings of the three independent transfections for
3T3 cells.
Generation of the ECR18 allele
A CRISPR/Cas9-based scheme was used to target a 395-bp genomic interval (mm9, chr7: 6,866,573–
6,866,967) termed ECR18 for deletion. In brief, 200 fertilized eggs were isolated from time-mated
C57BL/6J mice. The isolated eggs were injected with two single-stranded guide RNAs (5′ guide: 5′–
TGATCGATCATCACGATCACGG–3′ and 3′ guide: 5′–TCCACAAGCACTACTCCTCACGG–3′) along with
Cas9 mRNA. The injected eggs were then implanted into the uteruses of six pseudo-pregnant females, which
derived 39 live pups. The pups were screened for CRISPR-mediated deletion by PCR genotyping using the fol-
lowing primers: P1, 5′– GCAATCTTCTCCCCCGACTC–3′; P2, 5′–AGATCACATTTCCCAGGGGC–3′; P3,
5′–ACACCCGGAGCTATGAATGC–3′. PCR genotyping identified one female mouse with CRISPR-mediated
deletion of ECR18. The genotyping PCR products were then cloned and sequenced to confirm the actual dele-
tion of ECR18. The sequenced PCR products were aligned to the mouse genome using the UCSC genome
browser, which revealed that the CRISPR-based deletion scheme removed a 273-bp region of ECR18 (mm9, chr7:
6,866,588–6,866,861). The founder female mouse containing the deletion was bred to a C57BL/6J male mouse
to establish the ECR18 mouse line. F1 progeny were bred to transmit the ECR18 allele through both the
maternal and paternal germ lines.
Gene expression analyses
Total RNA was extracted from the mouse heads of 1-day-old neonates using the Trizol Reagent (Invitrogen).
Approximately 3.5 μg total RNA was converted to cDNA using random primers and M-MuLV Reverse Tran-
scriptase (NEB, Ipswich, MA, USA). Next, 1 μl of 0.5× (diluted) cDNA was used for quantitative real-time PCR
(QuantStudio 6, Invitrogen) using SYBR-green (Bio-Rad, Hercules, CA, USA). Three biological replicates for each
of the sexes were processed for wild-type (WT) and paternal or maternal deletion of Peg3-ECR18. Expression levels
of two internal controls, β-actin and Gapdh, were measured alongside those of Peg3, Usp29 and Zim1 in neonate
heads. Ct values for all genes (three technical replicates for each animal) were independently normalized, using
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Figure 6. Transcriptional regulation by Peg3-ECR18 and H19-HMR. Two constructs were used to test promoter
activity of the iHMR, in forward (dark colors in [B & C]) and reverse (light colors in [B & C]) orientations (A).
Peg3-ECR18 (B) and H19-HMR (C) showed promoter activity in HEK293T (orange) and 3T3 (green) cells, but not in
HeLa (gold) or Neuro2A (blue) cells. Luciferase activity from two constructs (D), without (hatched bars in [E & F]) and
with (solid bars in [E & F]) the iHMR cloned upstream of luc2 that was driven by the corresponding promoter in each
domain. Peg3-ECR18 showed enhancer activity in HEK 293T, HeLa and NIH 3T3 cells (E), whereas H19-HMR (F)
upregulated H19 in HEK293T but downregulated H19 in 3T3 cells. All luciferase activity is shown relative to that of
the promoterless luc2 (dotted line at 1). Error bars show standard deviation between technical replicates.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; *****p < 0.00001 (Student’s t-test).
iHMR: Intergenic/intronic hypomethylated region.
the 2Ct method [29], against both internal controls to determine the accuracy of fold changes observed. Relative
expression levels of Peg3, Usp29 and Zim1 were pooled for all replicates (technical and biological) of a particular sex
and genotype; statistical significance of expression level differences between WT and mutant was established using
the Mann–Whitney–Wilcoxon test (p < 0.05; RStudio). All mouse experiments were performed in accordance
with NIH guidelines for care and use of animals and also approved by the Louisiana State University Institutional
Animal Care and Use Committee, protocol #16-060.
Results
Identification of iHMR as potential enhancers for imprinted domains
Whole-genome bisulfite sequencing has revealed several iHMRs that do not correspond to a known promoter or
enhancer element. We visualized these regions located within five imprinted domains with the UCSC Genome
Browser showing DNA methylation profiles of adult mouse tissues, placenta [20] and embryonic stem (ES) cells
(Figure 1) [19]. We detected the largest number of iHMR [23] in the approximately 50 kb intronic region spanning
Gnas and Nespas (Gnas domain), 22 in the ∼200 kb intron of Usp29 (Peg3 domain) and 21 in the ∼100 kb
intergenic region upstream and downstream of Dlk1 (Gtl2/Dlk1 domain). Five iHMRs were noted in the ∼50 kb
intergenic spaces between Ndn, Magel2 and Mkrn3 (Ndn domain), and eight in the ∼40 kb region between
H19 and Igf2 (H19 domain) (Supplementary Figure 1). A large majority of the iHMR showed tissue-specific
hypomethylation patterns; however, a few of them showed hypomethylation in a majority of the tissues studied.
Although the former category has been previously shown to contain enhancer-like characteristics [11], the latter
has remained largely uncharacterized. Therefore, here we largely focused on those iHMR, which showed shared
hypomethylation patterns across multiple mouse tissues (Gnas-HMR, as an example in Figure 1A).
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Eight representative iHMRs were selected from the following imprinted domains – Gnas, Peg3, Ndn, H19 and
Dlk1 – and named based on the imprinted domain they were located in. The genomic location of each iHMR, along
with the nomenclature, is shown in Figure 1A–E. Since the Peg3-HMR was initially identified as ECR18, we retained
the established terminology. According to whole-genome bisulfite sequencing (Figure 2A), four iHMRs (Peg3-
ECR18, Ndn-HMR, H19-HMR and Dlk1-HMR2) were hypomethylated in all adult tissues as well as placenta.
The remaining four iHMRs (Gnas-HMR, Dlk1-HMR1, -HMR3 and -HMR4) were hypomethylated in a majority
of the tissues. Three of the iHMRs selected showed a constitutive hypomethylation pattern (hypomethylated in ES
cells as well as all adult tissues): Ndn-HMR, H19-HMR and Dlk1-HMR2 (Figure 2A).
In order to understand the potential functional significance of these iHMRs, we surveyed the histone modi-
fications at these regions [23]. The iHMRs were largely marked by H3K4me1 (monomethylation of lysine 4 on
histone H3) and/or H3K27ac (acetylation of lysine 27 on histone H3) (Figure 2B), indicating a potential enhancer
function for these regions [30]. We noted a unique case of H3K4 trimethylation on Peg3-ECR18 in the embryonic
heart tissue, suggesting tissue-specific promoter activity for this region. The greatest number of active histone marks
was observed in E14.5 tissues (heart, limb, brain and liver), placenta and adult olfactory bulb. This is consistent
with the fact that imprinted genes are mainly expressed during the embryonic and neonatal stages [7]. Therefore, the
overall histone profile suggested that the iHMRs may be tissue- and stage-specific enhancers for imprinted genes
in their respective domains.
DNA methylation status of iHMR in normal & tumor tissues
In order to validate the hypomethylation status of the iHMRs, we performed independent COmbined Bisulfite
Restriction Assay (COBRA) [31] analyses using the DNA from the six adult tissues representing the three germ layers.
According to the results (Figure 3A & Supplementary Figure 2A), five iHMRs appeared completely unmethylated
in most adult tissues (Peg3-ECR18, Ndn-HMR, Gnas-HMR, Dlk1-HMR1 and -HMR3), whereas the remainder
showed partial methylation patterns. The iHMRs also showed some tissue-specific methylation. Despite being
generally hypomethylated, Ndn-HMR (Figure 3A) and Peg-ECR18 (Supplementary Figure 2A) showed minor levels
of methylation in the brain; H19-HMR, Dlk1-HMR2 and -HMR3, on the other hand, showed higher methylation
levels in the liver, compared with the other tissues (Figure 3A). In order to test whether the hypomethylation status
of the loci in the adult tissues is set up earlier during development, we performed COBRA analyses on embryonic
tissues at 14.5 and 17.5 dpc. The iHMR loci appeared to have either none or very low levels of DNA methylation at
both embryonic stages (Figure 3B & Supplementary Figure 2B); thus indicating that the hypomethylation status at
the iHMRs is likely established during embryonic development and maintained in the adult tissues. In sum, this set
of DNA methylation analyses largely agreed with the next-generation sequencing (NGS)-based results (Figure 2A),
and confirmed the hypomethylation of the eight imprinted domain iHMRs selected for this study. Furthermore,
the COBRA data revealed subtle tissue-specific differences in methylation levels at the iHMRs, and a tendency for
greater methylation at some loci in the brain and liver.
Previously, it had been suggested that potential enhancer regions in imprinted domains (such as Peg3-ECR18)
may be epigenetically unstable in mouse thymic lymphoma [3]. Thus, we tested the methylation levels of the
remaining iHMRs at three stages of murine thymic lymphoma driven by a KrasG12D mutation [3]. Besides Peg3-
ECR18 (Supplementary Figure 2C), five other iHMRs also showed aberrant DNA methylation levels in the
thymic neoplasm (Figure 3C). For the most part, the iHMRs tended toward hypermethylation in the cancer tissue;
however, two iHMRs, H19-HMR and Dlk1-HMR1, which were partially methylated in the normal thymus,
became hypomethylated in the lymphoma. Given that the open chromatin at hypomethylated regions would
be susceptible to global epigenetic changes in cancer, it is interesting to note that Ndn-HMR and Gnas-HMR
showed no change and remained completely unmethylated in all tumor samples (Figure 3C). This suggests that
the epigenetic instability at imprinted domain iHMRs may not be simply an outcome of global changes to the
epigenome, but rather a functional response to the carcinogenesis process.
Imprinted genes have also been implicated in various human cancers [2]. In particular, various epigenetic changes
have also been noted at the associated ICRs and ECRs, including at the human ortholog of Peg3-ECR18 [2].
Thus, we assessed the methylation levels of the human orthologous regions of the iHMRs in six human samples:
two pairs of breast and lung tumors along with their matched normal tissues and two unmatched samples of
breast and lung cancer. The orthologous regions for the iHMRs in humans appeared largely hypomethylated in
the normal human breast and lung tissue, albeit with partial methylation at all loci except hNdn-HMR, hH19-
HMR and hDlk1-HMR2. Besides ECR18 (Supplementary Figure 2D), five other iHMRs showed aberrant DNA
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methylation in at least one of the human tumor samples (Figure 3D). The hGnas-HMR locus appeared the most
sensitive, responding to all four breast and lung tumor samples. At least three loci, hGnas-HMR, hDlk1-HMR1
and -HMR3, were deemed capable of responding specifically to carcinogenesis in the breast and/or lung, since they
showed aberrant methylation levels in at least one of the matched tumors. Two loci, hNdn-HMR and hH19-HMR,
showed no change in DNA methylation in any of the tumors, remaining completely unmethylated in all normal
and tumor samples (Figure 3D). Taken together, the seemingly targeted, nonglobal nature of epigenetic changes
observed at the human orthologs of the iHMRs, suggest that these elements may be functionally responsive to
cancer states in humans as well as in mice.
Conserved putative regulatory motifs found within iHMR
In order to further characterize potential functions of the iHMRs, we assessed the overall sequence conservation
levels at the hypomethylated loci in 40 placental mammals. Since many of the iHMRs spanned several kb, the most
conserved 100–500 bp segment was selected based on the conservation data available from the UCSC Genome
Browser [21]. The mouse iHMR sequence (Supplementary Material 1) was used as a reference to harness the
orthologous sequences in the other mammals, using the MultiZ alignment tool [22] and BLAT. The sequences
were then aligned against the mouse sequence, using the blastn program. The sequence identity (% ID) for each
alignment ≥100 bp was recorded, and has been represented as a grayscale in Figure 4. Except for Ndn-HMR and
Dlk1-HMR4, the iHMRs appeared conserved in a large number of mammalian species (Figure 4). Among the
conserved iHMRs, H19-HMR and Dlk1-HMR3 showed highest level of sequence identity in humans (∼88%)
and Dlk1-HMR2 showed the lowest (∼68%). The percentage ID between mouse and human for the remaining
three conserved iHMRs ranged from approximately 73–79% (Supplementary Figure 3A). Overall, six out of eight
imprinted domain iHMRs showed approximately 70–90% sequence identity between mice and humans, indicating
high degrees of sequence conservation at these regions.
Next, we overlapped publicly available ENCODE ChIP-seq data to identify any DNA-binding factors shared
among the iHMRs. We found enrichment for CTCF at Gnas-HMR, Ndn-HMR, H19-HMR and Dlk1-HMR2
in a majority of cell types, suggesting that they may be constitutive CTCF-binding sites [12]. Examination of the
ChIP-seq data from the human ENCODE project also revealed CTCF, SMC3 and RAD 21 (cohesin complex
factors) enrichment at the orthologous regions in humans. Furthermore, the identical CTCF-binding motif shared
by hGnas-HMR and mGnas-HMR was found in 26 of the 40 (65%) placental mammals (Supplementary Figure
3B). Similarly, the CTCF-binding motifs at H19-HMR and Dlk1-HMR2 were also conserved, with approximately
63 and 45% of the placental mammals, respectively, also harboring the identical sequence (‘C’ in Figure 4). We
further tested potential binding of CTCF to the iHMR through an independent series of ChIP experiments using
MEF cells (Figure 5). The results confirmed the binding at the four loci, whereas the remaining iHMRs showed no
significant enrichment (Figure 5). Together, these data suggest that CTCF may be the most obvious DNA-binding
protein that is involved in some unknown functions of the iHMR.
We also used the following bioinformatic approach to identify additional transcription factor motifs. We selected
five mammal sequences for each iHMR representing five mammalian orders, which were then used for predicting
potential binding motifs for known DNA-binding proteins with the DCODE program [27]. One of the motifs
conserved across multiple iHMRs turns out to be the E-box (enhancer-box); all except Ndn-HMR displayed some
form of the generic motif (CANNTG; ‘E’/’e’ in Figure 4 & Supplementary Figure 3). Therefore, we conducted
manual inspection of the 40 mammalian sequences to detect its presence within each iHMR. The E-box was
particularly conserved at Gnas-HMR and Dlk1-HMR3. The E-box motif is detected at these loci in approximately
85% of the species surveyed, with most species harboring the identical sequence as mouse (‘E’ in Figure 4 &
Supplementary Figure 3B). In some species, however, the exact sequence of the E-box varied from that in mouse,
but a generic motif for the E-box was still present (‘e’ in Figure 4). Interestingly, despite the poor overall conservation
status of Dlk1-HMR4, several placental mammals nonetheless harbor some form of the E-box motif in that region.
Consistent with a conserved E-box, we discovered putative-binding sites for E2A, MYOD and AP4 at Peg3-
ECR18 [8], Dlk1-HMR1, and Gnas-HMR (Table 1 & Supplementary Material 3), which are known to bind to
the E-box motif. Overall, these surveys identify the E-box motif as another frequent motif within the imprinted
domain iHMR.
Besides CTCF and E-box motifs, we also discovered other conserved motifs within the iHMRs (Table 1 &
Supplementary Material 3). Both Dlk1-HMR1 and -HMR2 showed putative binding domains for GATA-binding
factors, which are known to be over-represented at enhancer elements [32,33]. Putative motifs for hormone receptors
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Table 1. Conserved putative transcription factor-binding motifs in imprinted domain intergenic/intronic hypomethylated
region.
Locus Conserved putative transcription factor motifs
Gnas-HMR YY1, E12, MYOD, TAL1
Peg3-ECR18† MYOD, AP4, E2A, PITX2
H19-HMR ATF1, ATF3, ATF6, ATF2/CREBP1, T3R, CREB, CREBP1CJUN
Dlk1-HMR1 E2A, MYOD, AP4, MYOGENIN, MEF2, MEF2A/RSRFC4, GATA1, GATA2, GATA3, NF1
Dlk1-HMR2 GATA1, GATA2, GATA3, GATA6, WT1
Dlk1-HMR3 AR, PR, GR, POU3F2, POU1F1, PAX6, PAX8, HNF1, IPF1/PDX1, LHX3, IRF1, NKX2–5
A detailed summary of the results from DCODE analysis is provided as Supplementary Material 3.
†From reference [8] (not part of DCODE analysis in this study).
(e.g., AR, GR) were found on Dlk1-HMR3, along with motifs for neuronal proteins such as POU1F1, PAX6 and
PAX8. Motifs for sex hormone binding in a potential regulatory region for an imprinted gene is intriguing, since
many of them show a sexually dimorphic expression pattern [34]. Moreover, the putative-binding motifs for the
neuronal proteins are also interesting, given that Dlk1 is functionally important for neurogenesis [35,36]. Finally,
H19-HMR showed various cAMP response element-associated factors (e.g., CREB, ATF1 and ATF3), along with
putative-binding sites for T3R and the enhancer-binding protein JUN (an AP1 transcription factor subunit).
Altogether, the iHMRs showed several conserved putative binding domains for enhancer-associated transcription
factors [32]. Furthermore, many of the transcription factors, whose putative DNA-binding motifs are conserved at
the iHMRs, appear to be functionally relevant for the regulation of imprinted genes in the domain. These findings,
along with their epigenetic profile (Figure 2), support the hypothesis that some of these iHMRs may be potential
enhancer elements within imprinted domains.
Transcriptional regulation by Peg3-ECR18 & H19-HMR
To further test whether the iHMRs act as regulatory elements in imprinted domains, we conducted ChIP-qPCR
for RNA polymerase II (Pol II) in MEF cells (Figure 5). According to the results, five iHMRs were significantly
enriched for Pol II: Peg3-ECR18, H19-HMR, Dlk1-HMR2, HMR3 and HMR4. Of those, we could successfully
clone two loci, H19-HMR (also bound by CTCF) and Peg3-ECR18 (not bound by CTCF), in order to conduct
reporter assays in vitro.
Enhancer elements have been previously shown to harbor transcriptional potential [37,38]. Therefore, we first
conducted a series of promoter assays for the two iHMRs, using a set of constructs designed to compare promoterless-
luc2 basal expression with the two iHMRs cloned upstream of luc2 in both orientations (Figure 6A). According
to the results, both Peg3-ECR18 and H19-HMR showed the ability to drive luciferase expression in HEK 293T
and 3T3 cells. Although ECR18 appeared to have promoter functionality in an orientation-independent manner
in both cell lines, H19-HMR was only able to drive transcription in the forward orientation in HEK293T cells
(Figure 6B & C). However, neither of the iHMR showed any significant promoter activity in HeLa or Neuro2A
cells in either orientation. Thus, the promoter assays concluded that the two iHMRs possess the ability to drive
transcription, albeit in a tissue-specific manner. Moreover, the orientation-independent capacity of Peg3-ECR18
and H19-HMR to initiate transcription in HEK293T and/or 3T3 cells may be reminiscent of the bidirectional
transcription observed at many enhancers [37,38].
Next, we directly tested the potential enhancer/repressor activity of the loci by comparing luciferase expression
without and with the iHMRs cloned upstream of luc2, driven by the main promoter from each of the imprinted
domains (Figure 6D). The results suggested that ECR18 and H19-HMR may possess regulatory capacity, but act
in a context-dependent manner. We observed significant upregulation of Peg3 in HEK 293T, HeLa and 3T3 cells
with the upstream ECR18 (Figure 6E). H19-HMR, on the other hand, influenced H19 expression levels differently
based on the cell line. In HEK293T, the upstream HMR acted as a transcriptional enhancer for H19, whereas it
had a repressive effect in 3T3 cells (Figure 6F). We were unable to determine the regulatory potential of H19-
HMR in Neuro2A cells because of the lack of H19 promoter activity in this cell line. Overall, the reporter assays
demonstrated the cis-regulatory potential of Peg3-ECR18 and H19-HMR, and highlighted the context-dependent
nature of their activity.
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Figure 7. In vivo regulatory function of Peg3-ECR18 in Peg3 imprinted domain. Relative expression levels of Peg3, Usp29 and Zim1
(normalized to β-actin) for: (A & C) WT (dark blue) versus Peg3-ECR18 deletion on the paternal allele (light blue); and (B & D) WT (dark
red) versus Peg3-ECR18 deletion on the maternal allele (light red). Deletion of Peg3-ECR18 affected multiple genes in the Peg3 domain in
an allele- and sex-specific manner. Three biological replicates (individual bars) were tested for males (A & B) and females (C & D) of each
genotype. All expression levels are shown relative to that of the three WT animals (dotted line at 1). Error bars show standard deviation
between technical replicates for each biological replicate.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; *****p < 0.00001.
DELm: Maternal transmission of the deletion; DELp: Paternal transmission of the deletion; WT: Wild-type.
Sex-specific regulation of the Peg3 domain by ECR18 in vivo
Potential in vivo functions of the iHMR were further tested using a mutant mouse line, in which ECR18 was
deleted with the CRISPR/Cas9 genome editing protocol. For this series of analyses, we derived two sets of mutant
mice in the following manner. Male heterozygotes for the deletion of ECR18 were bred with female WT littermates
to derive the pups with the paternal transmission of the deletion (DELp), while the reciprocal cross yielded the
pups with maternal transmission of the deletion (DELm). These two sets of pups were used to test the potential
functions of ECR18 in an allele-specific manner. Since ECR18 was previously predicted to be active in the neonate
brain [9], total RNA was isolated from neonate heads for subsequent cDNA synthesis. The expression levels of
the three imprinted genes within the Peg3 domain, which are highly expressed in neonatal heads [9,39–42], were
measured as a proxy for ECR18 activity (Figure 7).
According to qRT-PCR analyses, deletion of ECR18 on the paternal allele in males resulted in significant
downregulation of the paternally expressed genes, Peg3 (∼50%) and Usp29 (∼60%) (Figure 7A). Downregulation
of the maternally expressed Zim1 was inconsistent across the three DELp male biological replicates, indicating
that it may be affected by extraneous factors, not related directly to the ECR18 deletion. However, the maternal
deletion of ECR18 resulted in consistent and significant downregulation of Zim1, by about 60%, in all three male
biological replicates (Figure 7B). In contrast, the paternally expressed genes were less affected in the DELm samples;
Peg3 showed no difference in gene expression, and Usp29 was downregulated by approximately 30% relative to
WT. These results strongly suggest that ECR18 functionally interacts with the promoters of Peg3/Usp29 and Zim1
regulating their transcriptional activity in an allele-specific manner. However, since no effect of ECR18 deletion on
either allele was observed in females (Figure 7C & D), we concluded that the modulation of imprinted genes by
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ECR18 is functional only in males. Taken together, the in vivo regulatory activity of Peg3-ECR18 suggest that the
iHMR may be involved in domain-wide regulation of imprinted genes in an allele- and sex-specific manner
Discussion
Recent whole-genomic bisulfite sequencing [19,20] have revealed several intergenic hypomethylated regions, whose
functional significance remain largely unknown. Here we have focused on a subset of intergenic and intronic
hypomethylated regions in imprinted domains (Figures 1 & 2A), which show hallmarks of regulatory elements. A
majority of them bear enhancer-associated histone marks in embryonic tissues known to express imprinted genes
(Figure 2B) [39,40,43–47] and are occupied by RNA polymerase II in MEF cells (Figure 5). Furthermore, most of the
iHMRs harbor various conserved putative transcription factor-binding motifs that are associated with enhancers
(Figure 4 & Table 1), and half of them appear to be constitutive CTCF-binding sites. A series of functional assays
further suggested that these elements have transcriptional-regulatory potential (Figure 6) and may be domain-wide
modulators of imprinted gene expression (Figure 7).
Imprinted genes are typically clustered within domains, where reciprocally imprinted genes are frequently co-
regulated. However, much of the mechanisms through which these genes are regulated remain uncharacterized.
Data from the ENCODE project have yielded many useful hints, and a few intergenic regions within imprinted
domains, such as H19-CCD (overlapping with H19-HMR) and Dlk1-CE4 (overlapping with Dlk1-HMR2), have
been shown to regulate Igf2 [18] and Dlk1 [10], respectively. Similarly, a survey on a number of ECRs in the Peg3
domain concluded that they might harbor some regulatory potential as well. However, apart from ICRs, few
other classes of regulatory elements have been characterized that have domain-wide regulatory functions. Here
we show that the deletion of a conserved intronic HMR in the Peg3 domain, ECR18, resulted in allele-specific
downregulation of multiple genes in the domain (Figure 7). The results suggest that in neonate brain, ECR18
modulates the expression levels of Peg3 and Usp29 on the paternal allele and Zim1 on the maternal allele in cis.
Thus, this is the first indication that ECR18 may serve as a domain-wide enhancer element for the Peg3 domain.
Given the similarities in the epigenetic profiles between ECR18 and many other iHMRs, we propose that other
intergenic hypomethylated regions may act as domain-wide regulators of imprinted genes as well. Thus, further
studies aimed at elucidating the roles of individual iHMRs are likely to yield important information regarding the
co-regulation of imprinted genes within a domain.
The various conserved putative transcription factor-binding sites at the iHMRs may offer a mechanistic clue
toward their regulatory potential. Of note, we found shared E-box-binding motifs across multiple imprinted
domain iHMRs (Figure 4), which is reminiscent of a similar finding across multiple ECRs in the Peg3 domain [8].
A large number of imprinted genes are associated with growth regulation, myogenic and neuronal cell lineages and
various mouse and human cancers [1–3,43,48]. A wide array of beta-Helix Loop Helix transcription factors that are
important for the same, such as MYOD, NEUROD and MYC, are known to bind the E-box [49]. Thus, the shared
E-box motif may offer a clue regarding how multiple imprinted genes might be regulated in varying contexts.
Many imprinted genes also share the unique feature that their expression levels are sexually dimorphic between
the two murine sexes [34]. Some iHMRs that show putative-binding motifs for sex hormone receptors (Table 1 &
Supplementary Material 3) may mediate such sex-specific expression patterns of imprinted genes. In that respect,
it is interesting to speculate the contribution of unknown sex-specific factors that mediate ECR18 activity only
in males, but not in females. Furthermore, many of the CTCF-binding iHMRs could be involved in organizing
parental allele-specific chromatin architecture, which may explain how nearby reciprocally imprinted genes are
co-regulated, such as in the case of Peg3 and Zim1 (Figures 4 & 7) [6,50]. Moreover, the conserved CTCF-binding
iHMRs (Figure 4) may be the key to understanding how the imprinting status and co-regulation of genes have
remained conserved throughout all placental mammals. Many of localized transcription factor-binding sites may
also help to understand associated imprinted gene function. For example, the conserved putative-binding sites
for cAMP response elements at H19-HMR is particularly interesting given that Igf2r is known to be regulated
by CREB in rats [51]. Similarly, the putative-binding sites for PAX6 at Dlk1-HMR3 could shed light on how the
nearby gene is regulated in the context of neurogenesis [36]. Therefore, future molecular and mutational analyses of
the various motifs within the iHMRs could be critical for understanding the regulatory importance of these regions
within imprinted domains.
Detailed functional characterization of iHMRs as domain-wide gene regulators could offer important clues
regarding the role of imprinted genes in cancer as well. Recent studies have implicated epigenetic instability
at ICRs, along with misregulation of imprinted genes, in the context of both mouse and human cancers [2,3].
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Methylation levels at putative enhancer regions (such as the iHMRs) also appeared sensitive to cancer states in both
species (Figure 3C & D) [2,3]. Currently, it is unknown whether the methylation status of these regulatory elements
could affect the expression level of imprinted genes; however, it is noteworthy that complete unmethylation at the
Peg3-ICR leads to misexpression of several imprinted genes in the domain [52], many of which are also affected
by ECR18 deletion (Figure 7). Based on that we propose that the methylation level at some of the ECR18-like
iHMRs may have a domain-wide effect on gene regulation, when altered in the cancer environment. It is most
likely that such an effect would be mediated through the activity of various transcription factors. In that respect, it
is interesting to note that several transcription factors whose putative-binding sites exist on iHMRs, such as CTCF,
MYOD, MYC and JUN, have been associated with various cancer states [53–56]. If the methylation status at iHMRs
and the subsequent misregulation of imprinted genes are causally linked to tumor progression, then these regions
could potentially be developed as novel targets of cancer therapy. Therefore, further studies aimed at understanding
the functional aspects of iHMRs in imprinted domains could not only reveal how imprinted genes are regulated
under normal circumstances, but the information could also have important applications in the context of cancer
formation and treatment.
Conclusion & future perspective
In this study, we have focused on a set of eight iHMRs, most of which are hypomethylated in a large number of
tissues and bear CTCF-binding sites. Previous studies have categorized iHMRs, which show shared hypomethylation
patterns in multiple tissues largely as promoter regions and those which bind CTCF as insulators. However, a subset
of those regions, such Peg3-HMR and H19-HMR, appear to function as enhancers. These noncanonical enhancer
iHMRs are generally well conserved and show histone marks and DNA-binding motifs, which are consistent with
their enhancer function. We confirmed their ability to both initiate transcription as well as affect the transcriptional
level of a nearby gene through reporter assays in multiple cell lines. Further, deletion of the Peg3-HMR in mice
resulted in allele- and sex-specific downregulation of several genes in the Peg3 domain, suggesting that the iHMR
may be responsible for domain-wide regulation of imprinted genes. Based on these evidences, we propose the
existence of noncanonical enhancer iHMRs within imprinted domains. These iHMRs are likely to hold the
mechanistic key to the co-regulation of oppositely imprinted genes within a domain by allowing for allele-specific
looping interactions. Future studies aimed at mutating or deleting these regions could yield important information
for imprinted domain regulation both in normal as well as disease states, such as cancer.
Summary points
• Most intergenic/intronic hypomethylated regions (iHMRs) can be categorized based on their methylation pattern
as follows: promoter, hypomethylated in multiple tissue types; enhancer, tissue-specific hypomethylation; or
insulator, CTCF-bound and hypomethylated in multiple tissues.
• Here we assayed eight iHMRs in five imprinted domains which comprise a subset that show a combination of
these patterns: hypomethylation in multiple tissues while also being bound by CTCF and harboring epigenetic
signatures of enhancer regions.
• Since many imprinting regulators remain unknown and the finding that the iHMRs tend to be epigenetically
unstable in multiple cancers, we further investigated their role in regulating imprinted genes, which are
themselves frequently misregulated during tumorigenesis.
• Analysis of 40 mammalian sequences indicated that most iHMRs are well conserved and harbor conserved E-box
and CTCF-binding motifs.
• Besides CTCF, chromatin immunoprecipitation assays also revealed RNA polymerase II occupancy at many of the
iHMRs, suggesting their potential role as regulatory elements.
• Two iHMRs, associated with the Peg3 and H19 imprinted domains, showed the context-dependent ability to drive
low-level transcription as well as regulate the transcriptional activity of Peg3 and H19, respectively.
• In vivo deletion of the Peg3-HMR resulted in allele- and sex-specific downregulation of multiple imprinted genes
within the Peg3 domain indicating the region may be a shared enhancer in the domain.
• Based on this evidence, we propose that the noncanonical iHMRs may be involved in allele-specific chromatin
looping in imprinted domains, thereby mediating the co-regulation of oppositely imprinted genes.
• Future mutational analysis of these regions is likely to reveal key information regarding imprinted gene
regulation, which may bear some clinical significance as well.
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